AtheroNova Inc. announced the release of preliminary findings from its Phase 1 clinical trial with its lead compound, AHRO-001. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova. The randomized, double-blind, placebo-controlled study enrolled more than fifty subjects and was conducted in Moscow, Russia.

Designed to characterize the safety, tolerability and pharmacokinetics of orally administered AHRO-001 in volunteers, all study subjects have completed dosing and follow-up. Data remain blinded at this time pending additional regulatory filings.